Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

169.70 +2.79 (+1.67%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

The Latest Analyst Ratings for Jazz Pharmaceuticals ↗

March 06, 2023

Via Benzinga

Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains ↗

March 02, 2023

It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers...

Via Benzinga

Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook ↗

March 02, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Earnings Preview For Jazz Pharmaceuticals ↗

February 28, 2023

Via Benzinga

Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says ↗

February 17, 2023

The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis.

Via Benzinga

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling ↗

February 13, 2023

The company only just gained approval for its depression drug in August.

Via Investor's Business Daily

Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart? ↗

January 06, 2023

Via Benzinga

2 Cannabis Stocks to Buy for the Long Haul ↗

December 31, 2022

Don't give up on this sector too quickly.

Via The Motley Fool

Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks ↗

December 21, 2022

Via Benzinga

GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow ↗

February 13, 2023

Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of...

Via Talk Markets

2 Cannabis Stocks That Could Make You Richer ↗

February 09, 2023

These two stocks could grow like weeds in the next five years and beyond.

Via The Motley Fool

CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS ↗

February 02, 2023

The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from...

Via Benzinga

3 Cannabis Stocks With Double-Digit Percentage Revenue Growth ↗

January 30, 2023

Their shares may be down, but their sales are up.

Via The Motley Fool

The Ultimate Growth Stocks to Buy With $300 Right Now ↗

January 29, 2023

These three companies should deliver inflation-busting long-term growth.

Via The Motley Fool

6 Analysts Have This to Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

2 Promising New Growth Stocks to Watch in 2023 ↗

January 23, 2023

These stocks have plenty of room to run.

Via The Motley Fool

Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer ↗

January 19, 2023

Via Benzinga

2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher ↗

January 11, 2023

There are still plenty of growth opportunities left for these businesses.

Via The Motley Fool

These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy. ↗

January 07, 2023

These stocks look cheap if you take a long-term view.

Via The Motley Fool

Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court ↗

January 05, 2023

Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS

Via Benzinga

2 Growth Stocks to Buy Heading Into 2023 ↗

December 30, 2022

These biotechs are far from having achieved their full potential.

Via The Motley Fool

2 Top Biotech Stocks to Buy for the Long Haul ↗

December 25, 2022

These mid-cap biotechs are solid long-term choices.

Via The Motley Fool

Better Buy: Moderna vs Axsome ↗

December 22, 2022

Revenue prospects look promising for both of these biotech companies.

Via The Motley Fool

Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 21, 2022

U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation...

Via Benzinga

After Jumping 100%, Is Axsome a Buy Before 2023? ↗

December 16, 2022

Axsome's revenue story is just getting started.

Via The Motley Fool

Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 09, 2022

Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on...

Via Benzinga

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗

December 08, 2022

These biotech players beat the bear market this year.

Via The Motley Fool

3 Fierce Stocks That Are Screaming Buys in December ↗

December 07, 2022

Here are three winners in the making.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.